471 patents
Page 5 of 24
Utility
RSV F Protein Mutants
13 Jul 23
The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.
Ye Che, Philip Ralph Dormitzer, Alexey Vyacheslavovich Gribenko, Luke David Handke, Avvari Krishna Prasad, Xiayang Qiu, Mark Edward Ruppen, Xi Song, Kena Anne Swanson, Srinivas Kodali, Xin Xu, KariAnn Sweeney Efferen, Ping Cai, Kristin Rachael Tompkins, Lorna del Pilar Nunez
Filed: 29 Mar 23
Utility
Orally Administered Combinations of Beta Lactam Antibiotics and Avibactam Derivatives for Treating Bacterial Infections
6 Jul 23
Pharmaceutical compositions comprising a β-lactam antibiotic and an avibactam derivative and methods of treating bacterial infections using the pharmaceutical compositions are disclosed.
Joaquim Trias, Carole Sable, Andrew Nicholls
Filed: 13 Mar 23
Utility
Formulations of Enzalutamide
6 Jul 23
This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
Filed: 11 Nov 22
Utility
Treatment of Type 2 Diabetes or Obesity or Overweight with 2-[(4-{6-[(4-CYANO-2-FLUOROBENZYL)OXY]PYRIDIN-2-YL}PIPERIDIN-1-YL)METHYL]-1-[(2S)-OXETAN-2-YLMETHYL]-1H-BENZIMIDAZOLE-6-CARBOXYLIC Acid or a Pharmaceutically Salt Thereof
29 Jun 23
The invention provides a method for treating T2DM, obesity or overweight or for weight management control by administering to an mammal (e.g. a human) in need thereof a pharmaceutical composition twice daily in an oral dosage form, wherein the pharmaceutical composition contains 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-5 [(2S)-oxetan-2-ylmethyl]-1H-benzimidazole carboxylic acid, or a pharmaceutically salt thereof [such as its tris salt].
Kai Teck Lee, Sweta Manthena, Aditi Rao Saxena
Filed: 24 Mar 21
Utility
Antineoplastic Combinations with m-TOR Inhibitor, Trastuzumab and/or HKI-272
29 Jun 23
A combination of temsirolimus and trastuzumab in the treatment of cancer is provided.
Laurence Moore, Charles Michael Zacharchuk, Sridhar Krishna Rabindran
Filed: 22 Jul 22
Utility
Beta-lactamase Inhibitors and Uses Thereof
29 Jun 23
β-Lactamase inhibiting compounds, therapeutic methods of using the β-lactamase inhibiting compounds, particularly in combination with β-lactam antibiotics and pharmaceutical compositions thereof are disclosed.
Eric M. Gordon, John Freund, Mark A. Gallop, Matthew Alexander James Duncton
Filed: 28 Feb 23
Utility
Recombinant Vaccinia Virus
29 Jun 23
The present disclosure provides a replication-competent, recombinant oncolytic vaccinia virus (RVV), compositions comprising the RVV, and use of the RVV or composition for inducing oncolysis in an individual having a tumor.
Joseph John Binder, Michael Dale Eisenbraun, Douglas Hanahan, David H. Kirn, Clare Lees, Prajit Limsirichai, Liliana Maruri Avidal
Filed: 5 Jan 21
Utility
Solid State Forms of (S)-2-(((S)-6,8-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)AMINO)-N-(1-(2-METHYL-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE and Uses Thereof
29 Jun 23
The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
Elaine GREER, Stephen ANDERSON, Mark MALONEY, Shu YU, Ekaterina ALBERT, Emily RIGSBEE
Filed: 17 Feb 23
Utility
Glycoconjugation Process
29 Jun 23
The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions.
Mingming Han, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad
Filed: 1 Mar 23
Utility
Methods of Inhibiting SARS-CoV-2 Replication and Treating Corona Virus Disease 2019
25 May 23
The invention relates to methods of treating COVID-19 in a patient by administering therapeutically effective amounts of certain SARS-CoV-2 inhibitor compounds or pharmaceutical compositions containing them to a patient in need thereof.
Padmavani Bezawada, Benjamin Joseph Burke, Emma Louise Hawking, Robert Louis Hoffman, Robert Steven Kania, Jonathan Richard Lillis, Matthew Nathan O'Brien Laramy, Klimentina Dimitrova Pencheva, Bradley Paul Sullivan, Andrew John Thiel, Martyn David Ticehurst
Filed: 3 Mar 21
Utility
Co-treatment with CDK4/6 and CDK2 Inhibitors to Suppress Tumor Adaptation to CDK2 Inhibitors
25 May 23
The invention provides a method for treating a disease or disorder, and preferably cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a CDK2 inhibitor, and a therapeutically effective amount of a CDK4/6 inhibitor, wherein the CDK4/6 inhibitor prevents rebound phosphorylation mediated by CDK4 and/or CDK6 in response to the inhibition of CDK2.
Mansi Arora, Stephen George Dann, Nichol Lee Goodman Miller, Sabrina Spencer, Todd Lee VanArsdale
Filed: 7 Apr 21
Utility
Crystalline Forms of 3-CYANO-1-[4-[6-(1-METHYL-1H-PYRAZOL-4-YL)PYRAZOLO[1,5-A]PYRAZIN-4-YL]-1H-PYRAZOL-1-YL]CYCLOBUTANEACETONITRILE, and Use Thereof
25 May 23
The present invention discloses novel crystalline forms of (1R,3R)-3-(cyanomethyl)-3-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-1H-pyrazol-1-yl)cyclobutane-1-carbonitrile, Form 1 anhydrous free base and Form 2 monohydrate, pharmaceutical composition containing them, preparations thereof and uses thereof.
Andrew James JENSEN
Filed: 5 Apr 21
Utility
Methods of Treating Coronavirus Disease 2019
18 May 23
The present invention is related to the discovery of new methods for treating the pathologic inflammatory response associated with patients infected with SARS-CoV-2 comprising administering orally to the patient in need of such treatment a therapeutically effective amount of a JAK inhibitor, a JAK/TYK inhibitor, or an IRAK4 inhibitor, or a combination thereof.
Michael Corbo, Spencer Ian Danto, Tamas Andras Koncz, Elena Peeva, Hernan Valdez, V, Michael Steven Vincent, Cara Margaret May Williams
Filed: 1 Apr 21
Utility
Boron Containing PDE4 Inhibitors
11 May 23
Tsutomu Akama, David Clive Blakemore, Robert Toms Jacobs, Peter Jones, David Christopher Limburg, Martins Sunday Oderinde, Matthew Alexander Perry, Jacob John Plattner, Joseph Walter Strohbach, Rubben Federico Torella, Thean Yeow Yeoh, Yasheen Zhou
Filed: 15 Dec 22
Utility
N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
11 May 23
Joseph P. LYSSIKATOS, Julie Marie HICKS, Fredrik P. MARMSATER, Qian ZHAO
Filed: 8 Sep 22
Utility
ANTI-GUCY2C Antibodies and Uses Thereof
11 May 23
The present invention is directed to antibodies that specifically bind to GUCY2c and methods of using such antibodies in the diagnosis and/or treatment of cancer.
Chew Shun CHANG, Divya MATHUR, Adam Reid ROOT
Filed: 14 Oct 21
Utility
Tricyclic Compounds and Their Use As Phosphodiesterase Inhibitors
11 May 23
Thomas Allen Chappie, Nandini Chaturbhai Patel, Patrick Robert Verhoest, Christopher John Helal, Simone Sciabola, Erik Alphie LaChapelle, Travis T. Wager, Ramalakshmi Yegna Chandrasekaran
Filed: 12 Oct 22
Utility
Method Of Preparing A Therapeutic Protein Formulation And Antibody Formulation Produced By Such A Method
4 May 23
The invention relates to a method of preparing a protein formulation including a therapeutic protein, the method comprising the steps of: providing a solution comprising said protein; concentrating the protein in the solution by a first ultra-filtration step; diafiltering the solution with a diafiltration buffer including at least one first excipient, whereby a retentate is obtained comprising the protein and the first excipient; further concentrating the protein in the retentate by a second ultra-filtration step; and adding at least one final excipient, whereby the protein formulation with a desired protein concentration is obtained.
Judy Kay GLYNN, Brian Xin CHEN, Daniel Patrick LACASSE
Filed: 8 Sep 16
Utility
Methods to Treat Cancer Using (R)-N-(3-FLUORO-4-((3-((1-HYDROXYPROPAN-2-YL)AMINO)-1H-PYRAZOLO[3,4-B]PYRIDIN-4-YL)OXY)PHENYL)-3-(4-FLUOROPHENYL)-1-ISOPROPYL-2,4-DIOXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXAMIDE
20 Apr 23
This invention relates to a method of treating cancer by administering to a patient in need thereof, over a period of time, therapeutic agents that comprises Compound 1 or a pharmaceutically acceptable salt thereof on an intermittent dosing schedule alone or in combination with a PD-1 or PD-L1 inhibitor, to a patient in need thereof.
Karyn Sue BOUHANA, Jim Yuk-Fai WONG
Filed: 1 Mar 21
Utility
Combination of an Anaplastic Lymphoma Kinase Inhibitor and a Cyclin Dependent Kinase Inhibitor
20 Apr 23
This invention relates to combination therapies comprising an inhibitor of anaplastic lymphoma kinase (ALK) and, an inhibitor of cyclin dependent kinase 4 and 6 (CDK4/6 inhibitor) or an inhibitor of cyclin dependent kinase 2, 4 and 6 (CDK2/4/6 inhibitor), and associated methods of treatment, combinations, pharmaceutical compositions and uses thereof.
Ping Wei, Scott Lawrence Weinrich
Filed: 2 Mar 21